Funding shifted. Pipelines matured. Clinical activity told a different story than the headlines suggested. This report compiles a full year of biopharma data across North America, Europe, and APAC, and layers in the strategic context that turns numbers into decisions.
Global biopharma funding tracked across North America, Europe, and APAC in 2025, including where investment concentrated, and where it contracted.
Raised by mid-sized biotechs across the globe, a segment that carries outsized commercial relevance for CRO and CDMO business development teams.
Unique clinical trial launches captured by Zymewire in 2025, surfaced in real time and compiled here as a leading indicator of where service demand is heading.
Most annual biopharma reports stop at funding. This one doesn't. The 2025 Recap brings together funding flows, pipeline activity, planned clinical trial disclosures, and study data across three regions, because these signals need to be read together, not in isolation. Built from Zymewire's intelligence on the biopharma sector, it's the kind of market view that commercial teams at CROs and CDMOs can actually build strategy around.
Full-year funding data across North America, Europe, and APAC, segmented by quarter, company size, therapeutic area, and pipeline maturity. A grounded look at where investment flowed in 2025, and where it pulled back.
A regional snapshot of drugs with documented activity in 2025, from preclinical through submission. Broken down by development phase, modality, and route of administration, this section maps the pipeline as it actually stood across all three regions.
Data without context is noise. This section draws from biopharma earnings calls and proprietary intelligence channels to surface the reasoning behind 2025's movements, what leadership was prioritizing, what they were stepping back from, and why.
Most reports tell you what happened. This section tells you what's coming. Zymewire tracks planned clinical trial disclosures as they surface, and this recap compiles a full year of that data, broken down by region, phase, and therapeutic area, giving commercial teams visibility before activity becomes public.
Trial starts and closeouts are more than operational milestones. Year-over-year initiation and closeout data across all three regions gives commercial teams a sharper read on where capacity demand is building, and where it's winding down.
We are obsessed with finding new ways to help your business generate more qualified leads. Our human-verified AI scans thousands of documents every day, separates the signal from the noise, and delivers value in the form of actionable sales intelligence.